{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:00:03Z","timestamp":1789077603614,"version":"build-2803163510"},"reference-count":106,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>Cardiovascular (CV) events in patients with cancer can be caused by concomitant CV risk factors, cancer itself, and anticancer therapy. Since malignancy can dysregulate the hemostatic system, predisposing cancer patients to both thrombosis and hemorrhage, the administration of dual antiplatelet therapy (DAPT) to patients with cancer who suffer from acute coronary syndrome (ACS) or undergo percutaneous coronary intervention (PCI) is a clinical challenge to cardiologists. Apart from PCI and ACS, other structural interventions, such as TAVR, PFO-ASD closure, and LAA occlusion, and non-cardiac diseases, such as PAD and CVAs, may require DAPT. The aim of the present review is to review the current literature on the optimal antiplatelet therapy and duration of DAPT for oncologic patients, in order to reduce both the ischemic and bleeding risk in this high-risk population.<\/jats:p>","DOI":"10.3390\/jcdd10040135","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T02:34:54Z","timestamp":1679625294000},"page":"135","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2779-0765","authenticated-orcid":false,"given":"Grigorios","family":"Tsigkas","sequence":"first","affiliation":[{"name":"Department of Cardiology, University Hospital of Patras, 265 04 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2332-4799","authenticated-orcid":false,"given":"Angeliki","family":"Vakka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital of Patras, 265 04 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2616-7952","authenticated-orcid":false,"given":"Anastasios","family":"Apostolos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital of Patras, 265 04 Patras, Greece"},{"name":"First Department of Cardiology, Hippocration General Hospital, National and Kapodistrian University of Athens, 157 72 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Bousoula","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tzaneio General Hospital, 185 36 Piraeus, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4217-3922","authenticated-orcid":false,"given":"Nikolaos","family":"Vythoulkas-Biotis","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital of Patras, 265 04 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8979-8554","authenticated-orcid":false,"given":"Eleni-Evangelia","family":"Koufou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital of Patras, 265 04 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8256-2928","authenticated-orcid":false,"given":"Georgios","family":"Vasilagkos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital of Patras, 265 04 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Tsiafoutis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, Red Cross Hospital, 115 26 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michalis","family":"Hamilos","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Heraklion University Hospital, 715 00 Heraklion, Crete, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4667-9181","authenticated-orcid":false,"given":"Adel","family":"Aminian","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Centre Hospitalier Universitaire de Charleroi, 6042 Charleroi, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Periklis","family":"Davlouros","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital of Patras, 265 04 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/eurheartj\/ehaa1109","article-title":"Ischaemic and bleeding risk in cancer patients undergoing PCI: Another brick in the wall","volume":"42","author":"Marenzi","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared Risk Factors in Cardiovascular Disease and Cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/ehf2.12551","article-title":"Recent advances in cardio-oncology: A report from the \u201cHeart Failure Association 2019 and World Congress on Acute Heart Failure 2019\u201d","volume":"6","author":"Anker","year":"2019","journal-title":"ESC Heart Fail."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/ejhf.1539","article-title":"Cancer and heart disease: Associations and relations","volume":"21","author":"Meijers","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/HEARTVIEWS.HEARTVIEWS_45_20","article-title":"Atherosclerosis, Ischemia, and Anticancer Drugs","volume":"22","author":"Singh","year":"2021","journal-title":"Heart Views"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/jth.12075","article-title":"Coagulation and cancer: Biological and clinical aspects","volume":"11","author":"Falanga","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Radmilovic, J., Di Vilio, A., D\u2019andrea, A., Pastore, F., Forni, A., Desiderio, A., Ragni, M., Quaranta, G., Cimmino, G., and Russo, V. (2020). The Pharmacological Approach to Oncologic Patients with Acute Coronary Syndrome. J. Clin. Med., 9.","DOI":"10.3390\/jcm9123926"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MOH.0000000000000072","article-title":"The coagulopathy of cancer","volume":"21","author":"Falanga","year":"2014","journal-title":"Curr. Opin. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/2048872617729636","article-title":"Treatment of patients with myocardial infarction depends on history of cancer","volume":"7","author":"Rohrmann","year":"2018","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3389\/fcvm.2021.669288","article-title":"Epidemiology of Cancer-Associated Thrombosis in Asia: A Systematic Review","volume":"8","author":"Lee","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.21037\/apm.2017.11.01","article-title":"Bleeding in cancer patients and its treatment: A review","volume":"7","author":"Johnstone","year":"2018","journal-title":"Ann. Palliat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jcin.2021.03.049","article-title":"Cancer Patients Have a Higher Risk of Thrombotic and Ischemic Events After Percutaneous Coronary Intervention","volume":"14","author":"Guo","year":"2021","journal-title":"JACC. Cardiovasc. Interv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S0049-3848(14)50009-6","article-title":"Bleeding complications during anticoagulant treatment in patients with cancer","volume":"133","author":"Kamphuisen","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/ATVBAHA.120.314378","article-title":"Cancer Therapy-Associated Thrombosis","volume":"41","author":"Grover","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1517\/14740338.2015.1052739","article-title":"Safety of anticoagulant treatment in cancer patients","volume":"14","author":"Wilts","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1111\/jth.15354","article-title":"Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancy","volume":"19","author":"Watson","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.beha.2008.12.001","article-title":"Epidemiology of cancer-related venous thromboembolism","volume":"22","author":"Wun","year":"2009","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/978-3-030-20315-3_13","article-title":"Bleeding Disorders Associated with Cancer","volume":"179","author":"Mantha","year":"2019","journal-title":"Cancer Treat. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/10245330500093237","article-title":"Management of bleeding in the terminally ill patient","volume":"10","author":"Prommer","year":"2005","journal-title":"Hematology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/eurheartj\/ehaa1032","article-title":"Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA","volume":"42","author":"Kwok","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_22","first-page":"21686","article-title":"Radiation-Induced Cardiovascular Disease: Review of an Underrecognized Pathology","volume":"10","author":"Eisenberg","year":"2021","journal-title":"J. Am. Heart Assoc. Cardiovasc. Cerebrovasc. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.5694\/mja2.50317","article-title":"5-Fluorouracil-induced acute coronary syndrome","volume":"211","author":"Das","year":"2019","journal-title":"Med. J. Aust."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ctrv.2013.03.005","article-title":"Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors","volume":"39","author":"Polk","year":"2013","journal-title":"Cancer Treat. Rev."},{"key":"ref_25","first-page":"OD05","article-title":"Cisplatin Induced Acute Myocardial Infarction and Dyslipidemia","volume":"11","author":"Hanchate","year":"2017","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_26","first-page":"E18","article-title":"Multiple coronary thrombi with cisplatin","volume":"26","author":"Karabay","year":"2014","journal-title":"J. Invasive Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Chen, X.L., Lei, Y.H., Liu, C.F., Yang, Q.F., Zuo, P.Y., Liu, C.Y., Chen, C.Z., and Liu, Y.W. (2013). Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: A meta-analysis. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0066721"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e27987","DOI":"10.4161\/onci.27987","article-title":"Adverse cardiac events to monoclonal antibodies used for cancer therapy","volume":"3","author":"Kounis","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jnci\/djr242","article-title":"Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: A systematic review and meta-analysis","volume":"103","author":"Amir","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bju.12905","article-title":"Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer","volume":"116","author":"Ziehr","year":"2015","journal-title":"BJU Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s00059-011-3444-5","article-title":"Sorafenib-associated multivessel coronary artery vasospasm","volume":"36","author":"Naib","year":"2011","journal-title":"Herz"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"590016","DOI":"10.3389\/fcvm.2021.590016","article-title":"Challenges and Management of Acute Coronary Syndrome in Cancer Patients","volume":"8","author":"Costa","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1200\/JCO.21.00693","article-title":"Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study","volume":"39","author":"Sabrie","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.hjc.2016.11.022","article-title":"Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer","volume":"58","author":"Kapelakis","year":"2016","journal-title":"Hell. J. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","article-title":"Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial","volume":"144","author":"Lopes","year":"2021","journal-title":"Circulation"},{"key":"ref_38","first-page":"244","article-title":"Optimal management of cancer patients with acute coronary syndrome","volume":"128","author":"Banasiak","year":"2018","journal-title":"Polish Arch. Intern. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"ehac544-2717","DOI":"10.1093\/eurheartj\/ehac544.2717","article-title":"Thirty-days versus standard duration of dual antiplatelet treatment after percutaneous coronary interventions: A systematic review and meta-analysis","volume":"43","author":"Apostolos","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40256-022-00559-0","article-title":"Very Short Versus Longer Dual Antiplatelet Treatment After Coronary Interventions: A Systematic Review and Meta-analysis","volume":"23","author":"Tsigkas","year":"2022","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/MCA.0000000000000986","article-title":"Cancer treatment resumption in patients with new-generation drug-eluting stents","volume":"32","author":"Balanescu","year":"2021","journal-title":"Coron. Artery Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"901431","DOI":"10.3389\/fcvm.2022.901431","article-title":"Percutaneous coronary intervention in patients with cancer using bare metal stents compared to drug-eluting stents","volume":"9","author":"Ahmed","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/14779072.2020.1759421","article-title":"Supporting evidence from optical coherence tomography for shortening dual antiplatelet therapy after drug-eluting stents implantation","volume":"18","author":"Ozaki","year":"2020","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"26","DOI":"10.31083\/j.rcm2401026","article-title":"Imaging of Left Main Coronary Artery; Untangling the Gordian Knot","volume":"24","author":"Apostolos","year":"2023","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ahj.2017.08.015","article-title":"\u201cBringing on the light\u201d in a complex clinical scenario: Optical coherence tomography-guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry)","volume":"194","author":"Iliescu","year":"2017","journal-title":"Am. Heart J."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Doolub, G., and Mamas, M.A. (2022). Percutaneous Coronary Angioplasty in Patients with Cancer: Clinical Challenges and Management Strategies. J. Pers. Med., 12.","DOI":"10.3390\/jpm12091372"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2459\/JCM.0000000000000993","article-title":"Acute coronary syndromes in cancer patients","volume":"21","author":"Bisceglia","year":"2020","journal-title":"J. Cardiovasc. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/ehjacc\/zuab056","article-title":"Evaluation and management of cancer patients presenting with acute cardiovascular disease: A Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: Acute coronary syndromes and acute pericardial diseases","volume":"10","author":"Gevaert","year":"2021","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Luc\u00e0, F., Parrini, I., Abrignani, M.G., Rao, C.M., Piccioni, L., Di Fusco, S.A., Ceravolo, R., Bisceglia, I., Riccio, C., and Gelsomino, S. (2022). Management of Acute Coronary Syndrome in Cancer Patients: It\u2019s High Time We Dealt with It. J. Clin. Med., 11.","DOI":"10.3390\/jcm11071792"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Tsigkas, G., Apostolos, A., Chlorogiannis, D.-D., Bousoula, E., Vasilagkos, G., Tsalamandris, S., Tsiafoutis, I., Katsanos, K., Toutouzas, K., and Aminian, A. (2023). Thirty-Days versus Longer Duration of Dual Antiplatelet Treatment after Percutaneous Coronary Interventions with Newer Drug-Eluting Stents: A Systematic Review and Meta-Analysis. Life, 13.","DOI":"10.3390\/life13030666"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Apostolos, A., Chlorogiannis, D., Vasilagkos, G., Katsanos, K., Toutouzas, K., Aminian, A., Alexopoulos, D., Davlouros, P., and Tsigkas, G. (2023). Safety and efficacy of shortened dual antiplatelet therapy after complex percutaneous coronary intervention: A systematic review and meta-analysis. Hell. J. Cardiol.","DOI":"10.1016\/j.hjc.2023.01.005"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Neumann","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ccd.28329","article-title":"SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019","volume":"94","author":"Baran","year":"2019","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1093\/eurheartj\/ehx531","article-title":"The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: A clinical conundrum","volume":"38","author":"McCarthy","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1200\/JOP.2017.028902","article-title":"Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary","volume":"14","author":"Schiffer","year":"2018","journal-title":"J. Oncol. Pract."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/VHRM.S140951","article-title":"Anemia and acute coronary syndrome: Current perspectives","volume":"14","author":"Stucchi","year":"2018","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_58","first-page":"145","article-title":"Ischemia and Bleeding in Cancer Patients Undergoing Percutaneous Coronary Intervention","volume":"1","author":"Ueki","year":"2019","journal-title":"Cardio Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","article-title":"A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study","volume":"22","author":"Gerotziafas","year":"2017","journal-title":"Oncologist"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/cam4.86","article-title":"Increased platelet reactivity in patients with late-stage metastatic cancer","volume":"2","author":"Cooke","year":"2013","journal-title":"Cancer Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/09537104.2018.1513475","article-title":"Dynamic platelet function is markedly different in patients with cancer compared to healthy donors","volume":"30","author":"Cowman","year":"2019","journal-title":"Platelets"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ajh.25512","article-title":"Platelet function tests predict bleeding in patients with acute myeloid leukemia and thrombocytopenia","volume":"94","author":"Sperling","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.mayocp.2020.05.044","article-title":"Coronary Artery Bypass Grafting in Cancer Patients: Prevalence and Outcomes in the United States","volume":"95","author":"Guha","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1161\/CIR.0000000000000182","article-title":"Secondary prevention after coronary artery bypass graft surgery: A scientific statement from the American Heart Association","volume":"131","author":"Kulik","year":"2015","journal-title":"Circulation"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/ejcts\/ezx314","article-title":"2017 EACTS Guidelines on perioperative medication in adult cardiac surgery","volume":"53","author":"Head","year":"2018","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jacc.2021.09.005","article-title":"2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Lawton","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/bloodadvances.2019001329","article-title":"First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: A systematic review and meta-analysis","volume":"4","author":"Vener","year":"2020","journal-title":"Blood Adv."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e017212","DOI":"10.1161\/JAHA.120.017212","article-title":"Safety and Efficacy of Double Antithrombotic Therapy With Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis","volume":"9","author":"Capodanno","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamacardio.2019.6175","article-title":"Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis","volume":"5","author":"Lopes","year":"2020","journal-title":"JAMA Cardiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamacardio.2019.1880","article-title":"Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials","volume":"4","author":"Lopes","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/eurheartj\/ehy162","article-title":"Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: A systematic review and meta-analysis of randomized clinical trials","volume":"39","author":"Golwala","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacc.2019.05.016","article-title":"Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review","volume":"74","author":"Capodanno","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1753944719891688","DOI":"10.1177\/1753944719891688","article-title":"Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting","volume":"13","author":"Buccheri","year":"2019","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): A randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(19)31954-3","article-title":"Dual antithrombotic therapy for atrial fibrillation and PCI","volume":"394","author":"Capodanno","year":"2019","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa1816885","article-title":"Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients","volume":"380","author":"Popma","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa1814052","article-title":"Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients","volume":"380","author":"Mack","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/ccd.28052","article-title":"An update on the management and outcomes of cancer patients with severe aortic stenosis","volume":"94","author":"Schechter","year":"2019","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"641268","DOI":"10.3389\/fcvm.2021.641268","article-title":"TAVR in Cancer Patients: Comprehensive Review, Meta-Analysis, and Meta-Regression","volume":"8","author":"Marmagkiolis","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5606\/tgkdc.dergisi.2021.20622","article-title":"Clinical outcomes after transcatheter aortic valve implantation in active cancer patients and cancer survivors","volume":"29","author":"Karaduman","year":"2021","journal-title":"Turk. J. Thorac. Cardiovasc. Surg."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.2174\/1381612826666200413083746","article-title":"Novel Perspective for Antithrombotic Therapy in TAVI","volume":"26","author":"Drakopoulou","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.jcin.2021.06.020","article-title":"Antithrombotic Therapy After Transcatheter Aortic Valve Replacement","volume":"14","author":"Capodanno","year":"2021","journal-title":"JACC. Cardiovasc. Interv."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"E177","DOI":"10.1002\/ccd.28498","article-title":"Antithrombotic strategies after transcatheter aortic valve implantation: Insights from a network meta-analysis","volume":"96","author":"Kuno","year":"2020","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jcin.2022.10.010","article-title":"No Antithrombotic Therapy After Transcatheter Aortic Valve Replacement: Insight From the OCEAN-TAVI Registry","volume":"16","author":"Kobari","year":"2023","journal-title":"JACC. Cardiovasc. Interv."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.2174\/1385272824999200427083838","article-title":"Antiplatelet and Antithrombotic Therapy After Patent Foramen Oval and Atrial Septal Defect Closure","volume":"26","author":"Drakopoulou","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s12016-021-08867-0","article-title":"Nickel Hypersensitivity to Atrial Septal Occluders: Smoke Without Fire?","volume":"62","author":"Apostolos","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"110442","DOI":"10.1016\/j.mehy.2020.110442","article-title":"New migraines after atrial septal defect occlusion. Is the nickel hypersensitivity the start of everything?","volume":"146","author":"Apostolos","year":"2021","journal-title":"Med. Hypotheses"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1093\/eurheartj\/ehy649","article-title":"European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism","volume":"40","author":"Pristipino","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1705915","article-title":"Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke","volume":"377","author":"Mas","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.jacc.2018.02.046","article-title":"Cryptogenic Stroke and High-Risk Patent Foramen Ovale: The DEFENSE-PFO Trial","volume":"71","author":"Lee","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1136\/hrt.2004.052258","article-title":"Closure of patent foramen ovale: Technique, pitfalls, complications, and follow up","volume":"91","author":"Meier","year":"2005","journal-title":"Heart"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.jcin.2019.04.002","article-title":"5-Year Experience of In-Hospital Outcomes After Percutaneous Left Atrial Appendage Closure in Germany","volume":"12","author":"Hobohm","year":"2019","journal-title":"JACC. Cardiovasc. Interv."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/14779072.2018.1510316","article-title":"Antithrombotic strategies after interventional left atrial appendage closure: An update","volume":"16","author":"Chen","year":"2018","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/europace\/euaa074","article-title":"Initial and long-term antithrombotic therapy after left atrial appendage closure with the WATCHMAN","volume":"22","author":"Ledwoch","year":"2020","journal-title":"Europace"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.amjcard.2020.08.013","article-title":"Safety and Efficacy of Single Versus Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion","volume":"134","author":"Patti","year":"2020","journal-title":"Am. J. Cardiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: The European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vasc","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1055\/s-0038-1649503","article-title":"Global Burden of Stroke","volume":"38","author":"Katan","year":"2018","journal-title":"Semin. Neurol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"CLXIII","DOI":"10.1177\/2396987321992905","article-title":"European Stroke Organisation (ESO) guidelines on management of transient ischaemic attack","volume":"6","author":"Fonseca","year":"2021","journal-title":"Eur. Stroke J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"E217","DOI":"10.1161\/STROKEAHA.120.033033","article-title":"Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient Ischemic Attack: Meta-Analysis of Randomized Controlled Trials","volume":"52","author":"Bhatia","year":"2021","journal-title":"Stroke"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1038\/s41467-019-13120-6","article-title":"Stroke among cancer patients","volume":"10","author":"Zaorsky","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5853\/jos.2019.02278","article-title":"Cancer-Related Stroke: An Emerging Subtype of Ischemic Stroke with Unique Pathomechanisms","volume":"22","author":"Bang","year":"2020","journal-title":"J. Stroke"}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/10\/4\/135\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:01:29Z","timestamp":1760122889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/10\/4\/135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":106,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["jcdd10040135"],"URL":"https:\/\/doi.org\/10.3390\/jcdd10040135","relation":{},"ISSN":["2308-3425"],"issn-type":[{"value":"2308-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]}}}